Fund Her Future Grant

Summary: The intent of the FY25 Toxic Exposures Research Program (TERP) Clinical Trial Partnership Award (CTPA) is to support new or existing collaborative partnerships that will rapidly implement clinical trials with the potential to have a significant impact on the prevention, treatment or management of symptoms, diseases, or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations. Distinctive Features: To encourage applications that include meaningful and productive collaborations between investigators, the FY25 TERP CTPA requires partnership of the Initiating Principal Investigator (PI) with at least one, and up to two, other collaborating PIs for the completion of one overarching study.

Purpose: This grant allows Skilled Nursing Facilities (SNFs) and associations on behalf of facilities to apply for funding for in-person visitation support materials. Description: CMP In-Person Visitation grants provide funding for nursing homes to facilitate safer in-person visits through use of outdoor and indoor equipment such as tents, clear dividers, portable fans, and portable room air cleaners with high-efficiency particulate air (HEPA, H-13 or 14) filters in response to the COVID-19 pandemic. Replacement air filters are a prohibited expense under this program. Facilities must attest they meet the requirements to purchase the materials and facilitate in-person visitation for residents. Facilities must be certified through the Centers of Medicare and Medicaid Services (CMS). Applicants may request up to a maximum of $3,000.00 per facility.

Transportation emissions remain the largest source of greenhouse gas pollution in the New Jersey, contributing to climate change impacts like rising temperatures, rising sea levels, and more extreme weather events. They also serve as a significant contributor for other air pollutants, like NOx and particulate matter, which have harmful environmental and health effects. Moving toward transportation electrification addresses these concerns because electric vehicles (EVs) do not produce any tailpipe emissions. New Jersey’s low-income communities and communities of color have historically been subject to an unreasonably high number of environmental and public health stressors, including transportation emissions. As a result, residents in these areas suffer from increased adverse health effects including, but not limited to, asthma, cancer, elevated blood lead levels, cardiovascular disease, and developmental disorders. Electric mobility solutions like carshare, rideshare, and ride hailing services provide additional modes of transport for residents in underserved areas, who often don’t own a personal vehicle and rely on public transportation. eMobility will help ensure they have access to and can benefit from the advantages of clean vehicle technology.

The Generating Income for Tomorrow (G.I.F.T.) Grant is designed to accelerate the growth of African American-owned businesses in Kansas City. It provides both capital and coaching to small businesses that demonstrate the potential for job creation and community impact. Grants for eligible businesses in the amount of $10,000 are available multiple times per year. There’s also an annual $100,000 grant awarded each year in July. Businesses must be at least 51 percent Black-owned and must be geographically located within the Kansas City, MO, city limits.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease.